Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dosimetry estimations for I-123-IAZA in healthy volunteers
Autore:
Stypinski, D; McQuarrie, SA; Wiebe, LI; Tam, YK; Mercer, JR; McEwan, AJB;
Indirizzi:
Univ Alberta, Dent Pharm Ctr 3118, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada Univ Alberta Edmonton AB Canada T6G 2N8 Sci, Edmonton, AB T6G 2N8, Canada Univ Alberta, Fac Med, Edmonton, AB T6G 2N8, Canada Univ Alberta EdmontonAB Canada T6G 2N8 Med, Edmonton, AB T6G 2N8, Canada MDS Pharma Serv, Lincoln, NE USA MDS Pharma Serv Lincoln NE USAMDS Pharma Serv, Lincoln, NE USA Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada Cross Canc Inst Edmonton ABCanada T6G 1Z2 , Edmonton, AB T6G 1Z2, Canada
Titolo Testata:
JOURNAL OF NUCLEAR MEDICINE
fascicolo: 9, volume: 42, anno: 2001,
pagine: 1418 - 1423
SICI:
0161-5505(200109)42:9<1418:DEFIIH>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
IODOAZOMYCIN ARABINOSIDE; TISSUE HYPOXIA; TUMOR HYPOXIA; BLOOD-FLOW; MARKERS; IAZA;
Keywords:
radiation dosimetry; hypoxia; pharmacokinetics; radiopharmaceuticals; I-123-iodoazomycin arabinoside;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: McQuarrie, SA Univ Alberta, Dent Pharm Ctr 3118, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada Univ Alberta Edmonton AB Canada T6G 2N8 AB T6G 2N8, Canada
Citazione:
D. Stypinski et al., "Dosimetry estimations for I-123-IAZA in healthy volunteers", J NUCL MED, 42(9), 2001, pp. 1418-1423

Abstract

I-123-Labeled iodoazomycin arabinoside (IAZA) is a marker of hypoxia in vivo. It has been used clinically to image hypoxic tissue in solid tumors, peripheral vascular disease of diabetic origin, blunt brain trauma, and rheumatoid joints and in an animal model of cerebrovascular disease. The radiation dose biodistribution for I-123-IAZA was studied to assess and characterize its suitability as a clinical radiopharmaceutical. Methods: Six healthy volunteers each received a nominal 185-MBq (5 mCi) dose of I-123-IAZA administered as a slow (1-3 min) intravenous injection in the arm. Anterior and posterior whole-body planar images were acquired for each volunteer beginning immediately after injection and at 1-2, 3-4, 6-8, and 20-24 h after injection. Venous blood samples (0 In predose through 28 h after dosing) and 28-h cumulative urine samples were taken from each volunteer for pharmacokinetic analysis. Radiation dose estimates were performed for all volunteers, with "reference adult" (for men) and "adult female" (for women) phantoms, and both the International Commission on Radiological Protection 30 gastrointestinal tract model and the dynamic bladder model, using the MIRDOSE3 program. Two sets of estimates, 1 using a pharmacokinetic analysis of total serum radioactivity and 1 based on scintigraphic image data, were obtained for each volunteer after I-123-IAZA administration. Results: Two compartments were discernible by pharmacokinetic analysis, and 4 compartments were discernible by image analysis. The urinary bladder wall received the greatest radiation dose (6.3E-02 +/- 8.7E-03 mGy/MBq), followed by the upper large intestinal wall (5.6E-02 +/- 1.2E-02 mGy/MBq), the lower large intestinal wall (5.0E-02 +/- 1.2E-02 mGy/MBq), and the thyroid (4.4E-02 +/- 1.4E-02 mGy/MBq). Approximately 90% of physiologically eliminated radioactivity was excreted through the kidneys. Radioactivity entering the intestinal tract from the gallbladder constituted < 10% of biologically eliminated activity. Conclusion: The dosimetric analysis of I-123-IAZA in 6 healthy volunteers indicated that both disposition kinetics and radiation dosimetry support its clinical use for imaging tissue hypoxia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 00:50:39